{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:26Z","timestamp":1793090306549,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105565","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:56:03Z","timestamp":1787669763000},"page":"105565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune checkpoint inhibitor combinations across clinically distinct metastatic renal cell carcinoma populations with limited or heterogeneous trial evidence: A systematic review, evidence map, and meta-analysis"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-3711","authenticated-orcid":false,"given":"Yiduo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2026.105565_bib1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.6004\/jnccn.2020.7578","article-title":"Performance status restriction in phase iii cancer clinical trials","volume":"18","author":"Abi Jaoude","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.21873\/anticanres.15557","article-title":"Comparative efficacy of combination therapy of ipilimumab plus nivolumab for non-clear cell renal cell carcinoma","volume":"42","author":"Bando","year":"2022","journal-title":"Anticancer. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.11124\/JBIES-22-00125","article-title":"Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105565_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105565_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1605282","article-title":"Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study","volume":"15","author":"Bourlon","year":"2025","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105565_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003281","article-title":"Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab","volume":"9","author":"Brown","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105565_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2022.11.013","article-title":"Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status","volume":"180","author":"Carril-Ajuria","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100101","article-title":"Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial","volume":"6","author":"Choueiri","year":"2021","journal-title":"ESMO Open."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105565_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","article-title":"New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors","volume":"12","author":"Ciccarese","year":"2016","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105565_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102530","article-title":"Real-world outcomes of first-line ipilimumab plus nivolumab in advanced renal cell carcinoma: a UK multi-centre retrospective study","volume":"24","author":"Crosby","year":"2026","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2026.102905","article-title":"Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada","volume":"17","author":"Curry","year":"2026","journal-title":"J. Geriatr. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105565_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11523-021-00832-3","article-title":"A multi-institutional, retrospective analysis of patients with metastatic renal cell carcinoma to bone treated with combination ipilimumab and nivolumab","volume":"16","author":"Desai","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105565_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1617743","article-title":"Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland","volume":"15","author":"Drobniak","year":"2025","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105565_bib15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105565_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1223282","article-title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","volume":"13","author":"Gr\u00fcnwald","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105565_bib17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: post hoc analysis of the CLEAR trial","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105565_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clgc.2019.11.012","article-title":"Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma","volume":"18","author":"Gupta","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7650","key":"10.1016\/j.critrevonc.2026.105565_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.critrevonc.2026.105565_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105565_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2025.06.011","article-title":"Real-world evidence from a retrospective multicentre analysis on first-line therapy for metastatic papillary renal cell carcinoma. A GUARDIANS project","volume":"78","author":"Hilser","year":"2025","journal-title":"Eur. Urol. Open. Sci."},{"key":"10.1016\/j.critrevonc.2026.105565_bib22","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clgc.2023.11.007","article-title":"Safety and efficacy of second-line TKI plus anti-PD1 in metastatic non-clear cell renal cell carcinoma: a real-world study","volume":"22","author":"Huang","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-19523-4","article-title":"Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: a multicenter retrospective study in Japan","volume":"15","author":"Iinuma","year":"2025","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105565_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105565_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/iju.15128","article-title":"Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study","volume":"30","author":"Izumi","year":"2023","journal-title":"Int. J. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105565_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102450","article-title":"Nationwide real-world outcomes of trial eligible and trial ineligible patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab","volume":"23","author":"Jespersen","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"issue":"Pt B","key":"10.1016\/j.critrevonc.2026.105565_bib28","article-title":"Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors","volume":"113","author":"Kato","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105565_bib29","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2340\/1651-226X.2025.44533","article-title":"Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab","volume":"64","author":"Kheir","year":"2025","journal-title":"Acta Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105565_bib30","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00262-026-04318-x","article-title":"Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study","volume":"75","author":"Maffezzoli","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105565_bib32","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s10147-025-02878-z","article-title":"Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab","volume":"30","author":"Mori","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105565_bib33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105565_bib34","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105565_bib35","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105565_bib36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105565_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11523-022-00896-9","article-title":"Efficacy and safety of immunotherapy-based combinations as first-line therapy for metastatic renal cell carcinoma in patients who do not meet trial eligibility criteria","volume":"17","author":"Nemoto","year":"2022","journal-title":"Target. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105565_bib38","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s11255-025-04486-2","article-title":"Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinoma","volume":"57","author":"Nemoto","year":"2025","journal-title":"Int. Urol. Nephrol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70186","article-title":"Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: subgroup analyses of post-marketing surveillance data by age","volume":"14","author":"Oya","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105565_bib40","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102470","article-title":"Ipilimumab and nivolumab in renal cell carcinoma: real-world experience in rare variant renal cell carcinoma, brain metastases and impact of immune-related adverse events and steroid use","volume":"24","author":"Peres","year":"2026","journal-title":"Clin. Genitourin. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105565_bib42","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.3390\/biomedicines10112758","article-title":"Impact of bone metastases on patients with renal cell carcinoma or melanoma treated with combotherapy ipilimumab plus nivolumab","volume":"10","author":"Pham","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15586\/jkcvhl.v11i3.352","article-title":"Clinical outcomes for metastatic renal cell carcinoma (mRCC) patients ineligible for front-line clinical trials","volume":"11","author":"Reynolds","year":"2024","journal-title":"J. Kidney Cancer VHL"},{"issue":"10189","key":"10.1016\/j.critrevonc.2026.105565_bib44","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105565_bib45","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105565_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial","volume":"79","author":"Rini","year":"2021","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105565_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41435-026-00385-3","article-title":"Immuno-molecular features and therapeutic implications of brain metastases in clear cell renal cell carcinoma patients","volume":"27","author":"Roodhooft","year":"2026","journal-title":"Genes. Immun."},{"key":"10.1016\/j.critrevonc.2026.105565_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105565_bib50","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/cancers17030522","article-title":"Real-world efficacy and toxicity of ipilimumab and nivolumab as first-line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients","volume":"17","author":"Shani Shrem","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/ijms24021096","article-title":"Pembrolizumab plus axitinib for metastatic papillary and chromophobe renal cell carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)","volume":"24","author":"Stellato","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105565_bib53","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ 355"},{"key":"10.1016\/j.critrevonc.2026.105565_bib54","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ 366"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib55","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105565_bib56","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jjco\/hyaa229","article-title":"Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma","volume":"51","author":"Tachibana","year":"2021","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105565_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.12.018","article-title":"Outcomes of patients with metastatic non-clear cell renal cell carcinoma receiving contemporary or traditional first-line therapies: results from the international metastatic renal cell carcinoma database consortium","author":"Takemura","year":"2026","journal-title":"Eur. Urol. Oncol. S2588-9311(25)00345-1"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100450","article-title":"Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105565_bib59","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jjco\/hyae108","article-title":"Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy","volume":"54","author":"Toyoda","year":"2024","journal-title":"Jpn J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib60","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1038\/s41598-025-33198-x","article-title":"Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma","volume":"16","author":"Toyoda","year":"2026","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105565_bib62","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.21873\/anticanres.17333","article-title":"Efficacy and safety of nivolumab with ipilimumab in elderly patients with advanced renal cell carcinoma","volume":"44","author":"Ueda","year":"2024","journal-title":"Anticancer. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10147-025-02933-9","article-title":"Comparison of first-line immuno-oncology combinations with molecular targeted therapy in patients with advanced renal cell carcinoma undergoing hemodialysis: a real-world multicenter retrospective study","volume":"31","author":"Ueda","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res. Synth. Methods"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105565_bib65","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2025.05.019","article-title":"First-line pembrolizumab plus lenvatinib for advanced non-clear-cell renal cell carcinoma: updated results from the phase 2 KEYNOTE-B61 trial","volume":"88","author":"Voss","year":"2025","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105565_bib66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12672-023-00816-x","article-title":"Geriatric nutritional risk index as a prognostic marker of first-line immune checkpoint inhibitor combination therapy in patients with renal cell carcinoma: a retrospective multi-center study","volume":"14","author":"Watari","year":"2023","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105565_bib67","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/cancers17030474","article-title":"Efficacy and safety of nivolumab plus ipilimumab for metastatic renal cell carcinoma in patients 75 years and older: multicenter retrospective study","volume":"17","author":"Yamashita","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105565_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00262-025-04293-9","article-title":"First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study","volume":"75","author":"Zhong","year":"2026","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600452X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600452X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:56:16Z","timestamp":1793087776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600452X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":68,"alternative-id":["S104084282600452X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105565","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor combinations across clinically distinct metastatic renal cell carcinoma populations with limited or heterogeneous trial evidence: A systematic review, evidence map, and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105565"}}